The company will receive Abbott’s insights from recent HeartMate 3 trials, including its support in designing the study, site ...

Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...

China: A recent study highlights the potential risks associated with sarcopenic obesity (SO) in diabetic patients with heart ...

Left ventricular assist devices, which are mechanical heart pumps, are an important treatment for patients with advanced ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized ...

observational European study, has shown a 1- and 2-year survival of 39 and 22%, respectively, in patients undergoing a LionHeart LVAD implantation. [12] This fully implantable device caused fewer ...

AI-assisted diagnosis of asymptomatic left ventricular dysfunction may detect disease early and thereby expedite treatment of ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients Cadrenal Therapeutics ...